New sickle cell drug DISC-3405 enters early human safety trial

NCT ID NCT07187973

Recruiting now Disease control Sponsor: Disc Medicine, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug, DISC-3405, in 24 adults with sickle cell disease to see if it is safe and how the body processes it. Participants will receive increasing doses of the drug, and researchers will monitor side effects and changes in blood counts. The goal is to gather initial safety data before larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SICKLE CELL DISEASE

Contacts and locations

Locations

Augusta University
RECRUITING

Augusta, Georgia, 30912, United States
Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27708, United States
Emory University
RECRUITING

Atlanta, Georgia, 30322, United States
Innovative Hematology - Indiana Hemophilia & Thrombosis Center
RECRUITING

Indianapolis, Indiana, 46260, United States
Mount Sinai Hospital
RECRUITING

New York, New York, 10029, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of Illinois Hospital and Health Sciences System
RECRUITING

Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.